Dataset from DNA Star SARS-CoV-2 Rapid Test

Background: The purpose of this study was to develop a novel, saliva-based aptamer detection assay capable of rapidly and accurately identifying SARS-CoV-2 infection. The goal was to create an automated, low-cost, and scalable diagnostic system that required minimal sample collection or preparation, addressing the urgent need for widespread testing during pandemics. By leveraging saliva as a sample medium, the study aimed to facilitate early detection, faster treatment initiation, and improved monitoring of infection progression, especially in individuals with pre-existing conditions such as diabetes, hypertension, or clotting disorders, who had elevated risk of severe complications from COVID-19.

Materials/Methods: This study outlined the development of a DNA star biosensing system that used aptamer based pattern recognition to detect SARS-CoV-2 antigens in saliva. The biosensor design was based on the virus’s unique spatial configuration of surface antigens, which enables multivalent binding to host cells. Researchers employed a rational design approach to create designer DNA nanostructures capable of “pattern matching” the antigenic geometry of SARS-CoV-2, thereby improving detection specificity and sensitivity. The biosensor design utilized multivalent, spatial epitope-pattern matching interactions and incorporated low-cost fabrication methods to allow scalable production at approximately $3 per test.

Outcome/Impact: This study proposed an innovative diagnostic platform that had the potential to revolutionize rapid testing during pandemics. The saliva-based DNA star biosensing assay offered high sensitivity and specificity at a fraction of the cost and time required for PCR testing, while eliminating the need for specialized laboratory infrastructure. By enabling frequent, accessible, and affordable testing, this technology could significantly improve public health surveillance, expedite isolation and treatment of infected individuals, and reduce disease transmission. The platform also established a foundation for future applications of aptamer based biosensing in detecting other infectious diseases.